[A18-40] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
|2018-09-17||Extract of dossier assessment||130 kB|
|2018-09-17||Dossier assessment (German version)||3 MB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Extract of dossier assessment
Federal Joint Committee (G-BA)
2018-12-20 A G-BA decision was published.